{"nctId":"NCT04592419","briefTitle":"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)","startDateStruct":{"date":"2020-09-25","type":"ACTUAL"},"conditions":["Macular Edema","Retinal Vein Occlusion"],"count":568,"armGroups":[{"label":"KSI-301 (Arm A)","type":"EXPERIMENTAL","interventionNames":["Drug: KSI-301","Other: Sham Procedure"]},{"label":"Aflibercept (Arm B)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aflibercept","Other: Sham Procedure"]}],"interventions":[{"name":"KSI-301","otherNames":[]},{"name":"Aflibercept","otherNames":["Eylea"]},{"name":"Sham Procedure","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Signed informed consent prior to participation in the study.\n2. Treatment-naïve macular edema of 6 months duration or less due to CRVO or BRVO. Participants with hemiretinal vein occlusion will be included as CRVO.\n3. BCVA ETDRS letter score between 80 and 25 (20/25 to 20/320 Snellen equivalent), inclusive in the Study Eye.\n4. CST of ≥ 320 microns on SD-OCT (Heidelberg Spectralis or equivalent on other OCT instruments) as determined by the Reading Center\n5. Decrease in vision determined by the Investigator to be primarily the result of ME secondary to RVO.\n6. Other protocol-specified inclusion criteria may apply.\n\nExclusion Criteria:\n\n1. Macular edema in the Study Eye for reasons other than RVO\n2. Active iris or angle neovascularization, neovascular glaucoma, neovascularization of the optic disc, retinal neovascularization or vitreous hemorrhage in the Study Eye.\n3. Uncontrolled glaucoma in the Study Eye.\n4. Active retinal disease other than the condition under investigation in the Study Eye.\n5. Any history or evidence of a concurrent ocular condition present, that in the opinion of the Investigator could require either medical or surgical intervention alter visual acuity during the study\n6. Active or suspected ocular or periocular infection or inflammation\n7. Any prior use of an approved or investigational treatment for macular edema secondary to RVO in the Study Eye (e.g. anti-VEGF, intraocular or periocular steroids, macular laser photocoagulation).\n8. Women who are pregnant or lactating or intending to become pregnant during the study.\n9. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg or diastolic value ≥100 mmHg while at rest\n10. Recent history (within the 6 months prior to screening) of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure or any acute coronary event.\n11. History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product.\n12. Other protocol-specified exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants.","description":"BCVA as a continuous variable measured at each study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA approach.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":".81"},{"groupId":"OG001","value":"15.6","spread":".79"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in All RVO Patients.","description":"BCVA as a continuous variable measured at each study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA approach.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":".83"},{"groupId":"OG001","value":"15.5","spread":".81"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in BCVA (ETDRS Letters) by Visit Over Time up to Week 48 for All RVO Participants.","description":"BCVA as a continuous variable measured at each study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA approach.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"9.25"},{"groupId":"OG001","value":"7.9","spread":"7.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"9.89"},{"groupId":"OG001","value":"11.2","spread":"10.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"10.38"},{"groupId":"OG001","value":"13.5","spread":"9.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"12.58"},{"groupId":"OG001","value":"14.2","spread":"10.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":"11.99"},{"groupId":"OG001","value":"14.9","spread":"10.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":"12.29"},{"groupId":"OG001","value":"15.3","spread":"11.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"11.42"},{"groupId":"OG001","value":"15.6","spread":"11.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"11.85"},{"groupId":"OG001","value":"14.1","spread":"12.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"11.55"},{"groupId":"OG001","value":"13.8","spread":"12.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"11.52"},{"groupId":"OG001","value":"13.5","spread":"11.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":"11.51"},{"groupId":"OG001","value":"13.9","spread":"12.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":"11.26"},{"groupId":"OG001","value":"13.7","spread":"13.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"12.10"},{"groupId":"OG001","value":"14.2","spread":"13.64"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Gain ≥ 5, ≥10 and ≥15 Letters From Baseline Over Time up to Week 48 for All RVO Participants.","description":"Number of participants in each treatment arm who meet specified criteria at each visit from Week 1 through Week 48. Percentages are 100\\*n/N.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"202","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"233","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"237","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"240","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199","spread":null},{"groupId":"OG001","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"233","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"213","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"212","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"175","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"179","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"181","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"183","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"168","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"137","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Lose ≥ 5, ≥10 and ≥15 ETDRS Letters From Baseline Over Time up to Week 48 for All RVO Participants","description":"Number of participants in each treatment arm who meet specified criteria at each visit from Week 1 through Week 48. Percentages are 100\\*n/N.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better Over Time (≥69 ETDRS Letters) for All RVO Participants.","description":"Percentage of participants with BCVA Snellen Equivalent of 20/40 or Better from Baseline to Week 48. Snellen Equivalent of 20/40 is 69 ETDRS letters. Number of participants in each treatment arm who meet specified criteria at each visit from Baseline through Week 48. Percentages are 100\\*n/N.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"182","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":null},{"groupId":"OG001","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"209","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"205","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"192","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (≤ 38 ETDRS Letters) Over Time for All RVO Participants.","description":"Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse from Baseline to Week 48. Snellen Equivalent of 20/200 is 38 ETDRS letters. Number of participants in each treatment arm who meet specified criteria at each visit from Baseline through Week 48. Percentages are 100\\*n/N.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Absence of Macular Edema (Defined as OCT CST < 325 Microns) Over Time for All RVO Participants.","description":"Macular Edema (ME) is assessed by optical coherence tomography (OCT) central subfield thickness (CST). A thickness of less than 325 microns is considered absence of ME. Proportion of participants with Absence of Macular Edema from Baseline to Week 48. Number of participants in each treatment arm who meet specified criteria at each visit from Week 1 through Week 48. Percentages are 100\\*n/N.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"225","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"240","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null},{"groupId":"OG001","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"196","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"177","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in OCT Central Subfield Retinal Thickness (CST) From Baseline by Visit Over Time for All RVO Participants.","description":"Mean change in OCT central subfield retinal thickness (CST) from baseline by visit over time (up to Week 48) for all RVO participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-225.2","spread":"152.87"},{"groupId":"OG001","value":"-255.9","spread":"168.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-230.8","spread":"181.37"},{"groupId":"OG001","value":"-294.2","spread":"195.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-255.6","spread":"190.40"},{"groupId":"OG001","value":"-310.1","spread":"203.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-195.8","spread":"213.70"},{"groupId":"OG001","value":"-314.8","spread":"208.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-264.9","spread":"204.77"},{"groupId":"OG001","value":"-321.0","spread":"209.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-218.1","spread":"203.88"},{"groupId":"OG001","value":"-323.0","spread":"209.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-278.9","spread":"192.68"},{"groupId":"OG001","value":"-326.6","spread":"210.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-240.4","spread":"200.78"},{"groupId":"OG001","value":"-273.9","spread":"218.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-246.6","spread":"200.99"},{"groupId":"OG001","value":"-269.7","spread":"213.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-243.4","spread":"198.13"},{"groupId":"OG001","value":"-258.6","spread":"213.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-246.9","spread":"193.79"},{"groupId":"OG001","value":"-274.9","spread":"229.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-237.5","spread":"189.30"},{"groupId":"OG001","value":"-258.3","spread":"216.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-240.0","spread":"203.97"},{"groupId":"OG001","value":"-278.8","spread":"224.13"}]}]}]},{"type":"SECONDARY","title":"Mean Change in OCT Center Point Retinal Thickness (CPT) From Baseline by Visit Over Time for All RVO Participants.","description":"Mean change in OCT center point retinal thickness (CPT) from baseline by visit over time (up to Week 48) for all RVO participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-278.7","spread":"186.23"},{"groupId":"OG001","value":"-320.9","spread":"200.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-278.5","spread":"212.92"},{"groupId":"OG001","value":"-358.4","spread":"224.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-301.4","spread":"220.72"},{"groupId":"OG001","value":"-373.9","spread":"235.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-230.3","spread":"248.92"},{"groupId":"OG001","value":"-377.6","spread":"239.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-311.5","spread":"237.01"},{"groupId":"OG001","value":"-381.3","spread":"240.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-258.1","spread":"236.58"},{"groupId":"OG001","value":"-385.4","spread":"238.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-327.9","spread":"223.13"},{"groupId":"OG001","value":"-387.5","spread":"240.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-280.5","spread":"232.22"},{"groupId":"OG001","value":"-328.0","spread":"249.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-288.9","spread":"229.6"},{"groupId":"OG001","value":"-322.4","spread":"244.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-286.8","spread":"229.63"},{"groupId":"OG001","value":"-308.1","spread":"247.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-290.7","spread":"220.56"},{"groupId":"OG001","value":"-328.7","spread":"261.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-281.5","spread":"221.38"},{"groupId":"OG001","value":"-306.6","spread":"252.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-279.6","spread":"231.43"},{"groupId":"OG001","value":"-331.6","spread":"259.43"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":284},"commonTop":["COVID-19","Hypertension","Conjunctival haemorrhage - Study eye"]}}}